Melanoma Clinical Trials in Philadelphia

Showing 161-180 of 326 trials

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

NCT02678741

Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.

Metastatic Melanoma

Elios Therapeutics, LLC26 participantsStarted Feb 2016

Birmingham, Alabama, United States • Santa Monica, California, United States • Miami Beach, Florida, United States +4 more locations

COMPLETEDPhase 1/2< 1 mile

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Uveal MelanomaOcular MelanomaChoroidal Melanoma

Aura Biosciences57 participantsStarted Feb 2017

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +10 more locations

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Study in Subjects With Small Primary Choroidal Melanoma

Melanoma Trials in Other Cities

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Other Conditions in Philadelphia